Try
LABCORP HOLDINGS INC.
LHUnited States
69 filed reports · 939 financial concepts · 2 earnings calls · 8 media appearances
Filed reports
69 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 164 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 7,700 | Jun 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 27 | 162 | Dec 2018 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 8,796 | Dec 2016 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 1 | Dec 2019 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 498 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 30, 2026 | 8 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 4, 2026 | 292 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 30, 2026 | 8 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 1,524 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 31, 2025 | 346 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 28, 2025 | 6 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 1, 2025 | 191 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 24, 2025 | 6 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 29, 2025 | 210 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | Apr 29, 2025 | 6 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 25, 2025 | 795 | Open |
Financial data
939 concepts · 16,659 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial907 concepts · 14,892 facts · Jun 2011 to Aug 2026
- Common Stock59 · Mar 2014 to Jun 2026
- Revenue59 · Mar 2014 to Jun 2026
- Amortization of intangible assets58 · Mar 2014 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Gross profit (US GAAP)58 · Mar 2014 to Jun 2026
- Income tax expense benefit58 · Mar 2014 to Jun 2026
- Net income loss58 · Mar 2014 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment before tax58 · Mar 2014 to Jun 2026
- Other comprehensive income loss tax58 · Mar 2014 to Jun 2026
- Stockholders equity (US GAAP)58 · Dec 2014 to Jun 2026
- Accumulated other comprehensive income loss defined benefit pension and other postretirement plans net of tax57 · Dec 2013 to Jun 2026
- Accumulated other comprehensive income loss foreign currency translation adjustment net of tax57 · Dec 2013 to Jun 2026
- Comprehensive income net of tax57 · Mar 2014 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest57 · Mar 2014 to Jun 2026
- Cost of revenue (US GAAP)57 · Mar 2014 to Jun 2026
- Income loss from equity method investments57 · Mar 2014 to Jun 2026
- Interest expense (US GAAP)57 · Mar 2014 to Jun 2026
- Investment income net57 · Mar 2014 to Jun 2026
- Net income loss attributable to noncontrolling interest57 · Mar 2014 to Jun 2026
- Operating income loss57 · Mar 2014 to Jun 2026
- Other comprehensive income loss before tax57 · Mar 2014 to Jun 2026
- Other comprehensive income loss net of tax57 · Mar 2014 to Jun 2026
- Other comprehensive income loss pension and other postretirement benefit plans adjustment before tax57 · Mar 2014 to Jun 2026
- Other nonoperating income expense57 · Mar 2014 to Jun 2026
Segment23 concepts · 1,318 facts · Mar 2014 to Jun 2026
- Covance Drug Development279 · Dec 2015 to Jun 2026
- Operating income loss178 · Mar 2014 to Jun 2026
- Revenue173 · Mar 2014 to Jun 2026
- Goodwill112 · Dec 2015 to Jun 2026
- Goodwill translation and purchase accounting adjustments96 · Dec 2015 to Jun 2026
- Goodwill acquired during period88 · Dec 2015 to Jun 2026
- Net restructuring charges62 · Dec 2015 to Dec 2021
- Property, Plant & Equipment, Net61 · Dec 2016 to Dec 2023
- Depreciation37 · Dec 2020 to Jun 2026
- Depreciation depletion and amortization37 · Mar 2014 to Dec 2021
- Labor and related expense28 · Dec 2022 to Jun 2026
- Other cost and expense operating28 · Dec 2022 to Jun 2026
- Supplies expense28 · Dec 2022 to Jun 2026
- Goodwill impairment loss22 · Dec 2019 to Dec 2024
- Biopharma Laboratory Services14 · Dec 2022 to Jun 2026
- Goodwill other increase decrease14 · Dec 2017 to Dec 2021
- LabCorp Diagnostics14 · Dec 2018 to Dec 2020
- Asset impairment charges12 · Dec 2015 to Sep 2019
- Intercompany revenue elimination10 · Dec 2014 to Dec 2017
- Goodwill written off related to sale of business unit8 · Dec 2017 to Sep 2019
- Goodwill and intangible asset impairment7 · Mar 2020 to Dec 2023
- New accounting pronouncement or change in accounting principle effect of adoption quantification6 · Dec 2016 to Dec 2017
- Impairment of intangible assets excluding goodwill4 · Dec 2020 to Dec 2021
Geography5 concepts · 287 facts · Dec 2016 to Jun 2026
- Covance Drug Development185 · Mar 2017 to Jun 2026
- Revenue46 · Dec 2016 to Jun 2026
- Property, Plant & Equipment, Net38 · Dec 2016 to Dec 2025
- Intercompany revenue elimination14 · Dec 2017 to Dec 2020
- Percent of Domestic Revenue4 · Mar 2025 to Jun 2026
Guidance4 concepts · 162 facts · Feb 2019 to Jul 2026
- EPS (Diluted) Guidance52 · Feb 2019 to Jul 2026
- Free Cash Flow Guidance52 · Feb 2019 to Jul 2026
- Revenue Growth Guidance52 · Feb 2019 to Jul 2026
- Revenue Guidance6 · Feb 2025 to Jul 2026
Segments
1,605 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments16 members · 1,318 facts
- Lab Corp Diagnostics385 · Mar 2014 to Mar 2025
- Covance Drug Development251 · Mar 2014 to Mar 2025
- Diagnostics230 · Dec 2018 to Jun 2026
- Biopharma Laboratory Services195 · Dec 2018 to Jun 2026
- Corporate73 · Mar 2014 to Jun 2026
- Covance drug development62 · Dec 2015 to Mar 2025
- Lab corp diagnostics59 · Dec 2015 to Mar 2025
- Biopharma laboratory services29 · Dec 2019 to Jun 2026
- Diagnostics21 · Dec 2019 to Jun 2026
- Genomic And Esoteric Testing3 · Dec 2014 to Mar 2016
- Routine Testing3 · Dec 2014 to Mar 2016
- All Other Segments2 · Dec 2016 to Dec 2017
- Clinicaldiagnosticslaboratory2 · Dec 2016 to Dec 2017
- Corporation1 · Sep 2019
- All other segments1 · Sep 2016
- Operating segments1 · Sep 2016
Statement geographicalsrt:StatementGeographicalAxis9 members · 235 facts
- US55 · Jun 2017 to Jun 2026
- Othercountries44 · Jun 2017 to Jun 2026
- Europe40 · Jun 2017 to Jun 2026
- North America30 · Dec 2018 to Jun 2026
- CA18 · Jun 2017 to Sep 2020
- CH18 · Jun 2017 to Sep 2020
- GB18 · Jun 2017 to Sep 2020
- Europe6 · Dec 2020 to Dec 2025
- North america6 · Dec 2020 to Dec 2025
Statement geographicalus-gaap:StatementGeographicalAxis11 members · 52 facts
- Othercountries10 · Dec 2016 to Dec 2025
- CA5 · Dec 2016 to Mar 2018
- CH5 · Dec 2016 to Mar 2018
- GB5 · Dec 2016 to Mar 2018
- Othercountries5 · Dec 2016 to Mar 2018
- Ca4 · Dec 2016 to Dec 2019
- Ch4 · Dec 2016 to Dec 2019
- Gb4 · Dec 2016 to Dec 2019
- Us4 · Dec 2016 to Dec 2019
- US4 · Dec 2016 to Mar 2018
- Europe2 · Mar 2017 to Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary116 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary158 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes14 claims from 1 reports · Dec 2025
- Risk factors90 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · Apr 2026 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 30, 2026
- FY2026 Q1Apr 30, 2026
Executive media
8 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews7 · Mar 2020 to Oct 2022
- Other appearances1 · Oct 2020
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.